Network meta-analysis showed no evidence of differences among all possible comparisons for secondary outcomes (MCV, homocysteine levels, platelet counts, and WBC counts)
They cover peptide basics, the preclinical evidence for BPC-157 and TB-500, mechanisms like angiogenesis and tissue repair, the lack of robust human trials, sourcing risks, regulatory bans, and the gap between anecdotal reports and scientific certainty
Always follow the specific handling directions provided with your prescription
Analytical verification procedures, including chromatographic purity profiling and mass spectrometry identity confirmation, are used to verify peptide identity, purity, and batch consistency
Limitations: FDA Category 2 substance